- Home
- FAMI vs TOVX Comparison
FAMI vs TOVX Comparison
Compare FAMI & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAMI
- TOVX
- Stock Information
- Founded
- FAMI 2015
- TOVX 2001
- Country
- FAMI China
- TOVX United States
- Employees
- FAMI N/A
- TOVX N/A
- Industry
- FAMI Packaged Foods
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- FAMI Consumer Staples
- TOVX Health Care
- Exchange
- FAMI Nasdaq
- TOVX Nasdaq
- Market Cap
- FAMI 3.1M
- TOVX 3.2M
- IPO Year
- FAMI 2018
- TOVX 2006
- Fundamental
- Price
- FAMI $0.32
- TOVX $1.47
- Analyst Decision
- FAMI
- TOVX Strong Buy
- Analyst Count
- FAMI 0
- TOVX 1
- Target Price
- FAMI N/A
- TOVX $6.00
- AVG Volume (30 Days)
- FAMI 300.7K
- TOVX 1.0M
- Earning Date
- FAMI 01-27-2025
- TOVX 11-12-2024
- Dividend Yield
- FAMI N/A
- TOVX N/A
- EPS Growth
- FAMI N/A
- TOVX N/A
- EPS
- FAMI 0.13
- TOVX N/A
- Revenue
- FAMI $86,261,500.00
- TOVX N/A
- Revenue This Year
- FAMI N/A
- TOVX N/A
- Revenue Next Year
- FAMI N/A
- TOVX N/A
- P/E Ratio
- FAMI $2.44
- TOVX N/A
- Revenue Growth
- FAMI N/A
- TOVX N/A
- 52 Week Low
- FAMI $0.17
- TOVX $1.14
- 52 Week High
- FAMI $2.35
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- FAMI 57.12
- TOVX 53.81
- Support Level
- FAMI $0.27
- TOVX $1.40
- Resistance Level
- FAMI $0.33
- TOVX $2.08
- Average True Range (ATR)
- FAMI 0.03
- TOVX 0.13
- MACD
- FAMI 0.00
- TOVX 0.06
- Stochastic Oscillator
- FAMI 79.14
- TOVX 35.11
About FAMI Farmmi Inc.
Farmmi Inc is a supplier of agricultural products. The products of the company are Shiitake Mushroom, Mu Er Mushroom and other edible fungi and other agricultural products. The majority of products are sold in mainland China.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.